PolyPid Ltd. PYPD

Company Overview

PolyPid Ltd. is a clinical-stage biopharmaceutical company focused on developing localized, prolonged-release therapeutics based on its proprietary polymer-lipid encapsulation technology. The company primarily operates in the biotechnology and pharmaceutical industries, with a strategic emphasis on preventing post-surgical infections and improving localized drug delivery. PolyPid’s lead product candidate is D-PLEX100, an investigational antibiotic therapy designed to provide sustained local delivery of doxycycline directly at surgical sites to help prevent surgical site infections (SSIs). The company’s technology platform is intended to enhance efficacy while reducing systemic exposure associated with conventional antibiotic administration.

PolyPid was founded in Israel and later became publicly traded on the Nasdaq Capital Market under the ticker PYPD. The company evolved from early-stage drug delivery research into a focused clinical-stage biotechnology organization centered on surgical infection prevention. Its positioning is based on the potential advantages of localized sustained-release therapeutics, particularly in high-risk surgical procedures where infection rates remain clinically and economically significant. Public disclosures in SEC filings and corporate materials indicate that the company’s strategy centers on leveraging its proprietary PLEX technology platform across additional therapeutic applications beyond D-PLEX100.